Lead (Ph 2) cell replacement candidate: OpRegen®, retinal pigment epithelium transplant therapy: Dry AMD. Lead cell delivery clinical program: Renevia®: med device developed as alternative to adipose tissue transfer procedures. Equity in Asterias Biotherapeutics (NYSE: AST), OncoCyte Corporation (NYSE: OCX), and AgeX Therapeutics (private)
1010 Atlantic Avenue, Suite 102
Alameda, CA 94501-1147
Send Message to Request Information
Log in to download presentation, request a 1x1 meeting, view additional roadshows, and more.
Stock Market Data
Market Data copyright © 2017 QuoteMedia.
Data delayed 15 minutes unless otherwise indicated (view
delay times for all
exchanges). RT=Real-Time, RTB=Real-Time
BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time
NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of
Day, PD=Previous Day. Market Data powered by